PCSK9 and glycogen storage disease VI: These therapeutic interventions include monoclonal antibodies and RNAinterference targeting PCSK9, statins targeting HMGCR,obicetrapib for CETP inhibition and volanesorsen for APOC3.Several prior studies have utilized drug targets of PCSK9 andHMGCR to explore their effects across diverse health domains, includingcardiovascular diseases, diabetes, cancer, and neurocognitive function [25, 27, 37, 38].